ZZ Biotech Announces Preliminary Phase 2 Stroke Trial Results
ZZ Biotech Announces Preliminary Phase 2 Stroke Trial Results with 3K3A-APC Houston, TX, USA, January...
ZZ Biotech Announces Preliminary Phase 2 Stroke Trial Results with 3K3A-APC Houston, TX, USA, January...
480 Biomedical develops new technology which imparts metal-like strength on bioresorbable polymers WATERTOWN, Mass., Nov. 21,...
Acquisition to Strengthen Company's Electrophysiology Portfolio and Expand into "Single-Shot" Balloon Pulmonary Vein Isolation Treatments...
Interview with Michael Mazzini, MD Author(s): Interview by Jodie Elrod Issue Number: Volume 17 -...
Phase 3-ready program complements Biogen’s ongoing development efforts in stroke Biogen will pay a $120...
Link to publication below: Mellitus Study Mentioned in "What to Expect" Magazine